Skip to content
10-Q/A

Quarterly Report

UNIGENE LABORATORIES INC

0001437749-13-000965

← back to feed
Filed
Jan 31, 2013 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2012 · Apr 26, 2012 95.37M sh
Capex Q1 2012 · Mar 31, 2012 $107.18K
Capex Q1 2012 · Mar 31, 2011 $5.38K
Operating Cash Flow Q1 2012 · Mar 31, 2012 −$115.01K
Operating Cash Flow Q1 2012 · Mar 31, 2011 −$3.99M
Cash And Equivalents Q1 2012 · Mar 31, 2012 $3.73M
Cash And Equivalents Q1 2012 · Dec 31, 2011 $4.68M
Cash And Equivalents Q1 2012 · Mar 31, 2011 $8.15M
Cash And Equivalents Q1 2012 · Dec 31, 2010 $12.2M
Stockholders Equity restated Q1 2012 · Mar 31, 2012 −$68.5M
Stockholders Equity restated Q1 2012 · Dec 31, 2011 −$65.7M
Current Liabilities restated Q1 2012 · Mar 31, 2012 $54.35M
Current Liabilities Q1 2012 · Dec 31, 2011 $5.7M
Total Liabilities restated Q1 2012 · Mar 31, 2012 $83.02M
Total Liabilities restated Q1 2012 · Dec 31, 2011 $83.89M
Current Assets restated Q1 2012 · Mar 31, 2012 $7.31M
Current Assets Q1 2012 · Dec 31, 2011 $10.29M
Total Assets restated Q1 2012 · Mar 31, 2012 $14.52M
Total Assets restated Q1 2012 · Dec 31, 2011 $18.2M
Eps Diluted restated Q1 2012 · Mar 31, 2012 −$0.03
Eps Diluted restated Q1 2012 · Mar 31, 2011 −$0.35
Sga Expense Q1 2012 · Mar 31, 2012 $2.09M
Sga Expense Q1 2012 · Mar 31, 2011 $1.97M
Rd Expense Q1 2012 · Mar 31, 2012 $1.26M
Rd Expense Q1 2012 · Mar 31, 2011 $2.42M
Net Income restated Q1 2012 · Mar 31, 2012 −$3.2M
Net Income restated Q1 2012 · Mar 31, 2011 −$32.79M
Operating Income Q1 2012 · Mar 31, 2012 −$2.71M
Operating Income Q1 2012 · Mar 31, 2011 −$3.63M
Cost Of Revenue Q1 2012 · Mar 31, 2012 $246.36K
Cost Of Revenue Q1 2012 · Mar 31, 2011 $264.9K
Revenue Q1 2012 · Mar 31, 2012 $1.75M
Revenue Q1 2012 · Mar 31, 2011 $2.13M